外汇新闻

Court Orders Elon Musk To Testify In SEC's Twitter Probe

Court Orders Elon Musk To Testify In SEC's Twitter Probe

A U.S. Federal judge ordered Tesla Inc. and SpaceX CEO Elon Musk to testify in an investigation by the U.S. Securities and Exchange Commission regarding his 2022 acquisition of social media platform Twitter, now re-branded as X. The federal regulator is probing whether Musk or anyone else, committed securities fraud in 2022 as he purchased Twitter stock ahead of his buyout of the firm.
RTTNews | 549天前
Takeda Says FDA Approves EOHILIA To Treat Eosinophilic Esophagitis

Takeda Says FDA Approves EOHILIA To Treat Eosinophilic Esophagitis

Japan's Takeda Pharmaceutical Co. Ltd. (TAK) announced Monday that the U.S. Food and Drug Administration (FDA) has approved EOHILIA (budesonide oral suspension), the first and only FDA-approved oral therapy for people 11 years and older with eosinophilic esophagitis (EoE)1 It will be available in 2 mg/10 mL convenient, single-dose stick packs by the end of February.
RTTNews | 550天前
Bay Street Likely To Open On Subdued Note

Bay Street Likely To Open On Subdued Note

Canadian shares are likely to open flat or slightly lower Monday morning, tracking weak crude oil prices. With U.S. inflation data due on Tuesday, the mood is likely to remain cautious and activity is expected to be mostly stock specific.
RTTNews | 550天前
India Inflation Softens On Cooling Food Costs

India Inflation Softens On Cooling Food Costs

India consumer price inflation softened to a three-month low in January on moderating food price growth, data from the Ministry of Statistics and Programme Implementation showed Monday. The consumer price index posted an annual growth of 5.10 percent, weaker than the 5.69 percent increase in December, which was the fastest in four months.
RTTNews | 550天前
more news
Merck Says Health Canada Oks KEYTRUDA In Combination With Trastuzumab And Chemotherapy

Merck Says Health Canada Oks KEYTRUDA In Combination With Trastuzumab And Chemotherapy

Merck & Co., Inc. (MRK), known as MSD outside the U.S. and Canada, announced Monday that Health Canada has granted approval of KEYTRUDA (pembrolizumab), Merck's anti-PD-1 therapy, in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adult patients with locally advanced unresectable or metastatic HER2 positive gastric or gastroesophageal junction (GEJ) adenocarcinoma, whose tumors express PD-L1 as determined by a validated test.
RTTNews | 550天前
Yen Rises Against Majors

Yen Rises Against Majors

The Japanese yen weakened against other major currencies in the European session on Monday.
RTTNews | 550天前

Stay up to date!

Add 新闻 to your browser

Extension Picture